Thermo Fisher Scientific Inc. (0R0H.L)
USD 523.04
(-1.93%)
USD 523.04
(-1.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.22 Billion USD | -21.93% |
| 2022 | 19.5 Billion USD | -3.63% |
| 2021 | 20.23 Billion USD | 22.59% |
| 2020 | 16.5 Billion USD | 39.55% |
| 2019 | 11.82 Billion USD | 4.07% |
| 2018 | 11.36 Billion USD | 14.13% |
| 2017 | 9.95 Billion USD | 12.96% |
| 2016 | 8.81 Billion USD | 7.73% |
| 2015 | 8.18 Billion USD | 3.33% |
| 2014 | 7.91 Billion USD | 37.7% |
| 2013 | 5.75 Billion USD | 4.25% |
| 2012 | 5.51 Billion USD | 10.59% |
| 2011 | 4.98 Billion USD | 9.07% |
| 2010 | 4.57 Billion USD | 10.22% |
| 2009 | 4.14 Billion USD | -1.35% |
| 2008 | 4.2 Billion USD | 10.56% |
| 2007 | 3.8 Billion USD | 142.62% |
| 2006 | 1.56 Billion USD | 31.22% |
| 2005 | 1.19 Billion USD | 17.79% |
| 2004 | 1.01 Billion USD | 7.01% |
| 2003 | 948.01 Million USD | 2.23% |
| 2002 | 927.37 Million USD | -3.26% |
| 2001 | 958.62 Million USD | -6.19% |
| 2000 | 1.02 Billion USD | -15.29% |
| 1999 | 1.2 Billion USD | -34.55% |
| 1998 | 1.84 Billion USD | 7.11% |
| 1997 | 1.72 Billion USD | 23.78% |
| 1996 | 1.39 Billion USD | 28.39% |
| 1995 | 1.08 Billion USD | 50.58% |
| 1994 | 719 Million USD | 33.99% |
| 1993 | 536.6 Million USD | 45.34% |
| 1992 | 369.2 Million USD | 25.03% |
| 1991 | 295.3 Million USD | 11.43% |
| 1990 | 265 Million USD | 35.97% |
| 1989 | 194.9 Million USD | 11.44% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.21 Billion USD | -6.21% |
| 2024 Q3 | 4.41 Billion USD | -0.37% |
| 2024 Q2 | 4.34 Billion USD | 3.01% |
| 2023 Q2 | 4.36 Billion USD | 2.13% |
| 2023 Q3 | 4.42 Billion USD | 1.49% |
| 2023 Q4 | 4.49 Billion USD | 1.51% |
| 2023 FY | 15.22 Billion USD | -21.93% |
| 2023 Q1 | 4.27 Billion USD | -9.76% |
| 2022 Q4 | 4.73 Billion USD | 6.86% |
| 2022 Q1 | 5.6 Billion USD | 3.78% |
| 2022 Q2 | 4.73 Billion USD | -15.6% |
| 2022 FY | 19.5 Billion USD | -3.63% |
| 2022 Q3 | 4.43 Billion USD | -6.32% |
| 2021 FY | 20.23 Billion USD | 22.59% |
| 2021 Q1 | 5.34 Billion USD | -5.88% |
| 2021 Q2 | 4.68 Billion USD | -12.36% |
| 2021 Q3 | 4.79 Billion USD | 2.33% |
| 2021 Q4 | 5.4 Billion USD | 12.57% |
| 2020 Q1 | 2.86 Billion USD | -9.31% |
| 2020 Q4 | 5.68 Billion USD | 27.54% |
| 2020 Q2 | 3.5 Billion USD | 22.2% |
| 2020 FY | 16.5 Billion USD | 39.55% |
| 2020 Q3 | 4.45 Billion USD | 27.28% |
| 2019 Q1 | 2.83 Billion USD | -7.12% |
| 2019 Q2 | 2.82 Billion USD | -0.32% |
| 2019 Q3 | 2.88 Billion USD | 2.3% |
| 2019 Q4 | 3.15 Billion USD | 9.38% |
| 2019 FY | 11.82 Billion USD | 4.07% |
| 2018 Q1 | 2.7 Billion USD | -3.15% |
| 2018 Q4 | 3.04 Billion USD | 16.6% |
| 2018 FY | 11.36 Billion USD | 14.13% |
| 2018 Q3 | 2.61 Billion USD | -4.49% |
| 2018 Q2 | 2.73 Billion USD | 1.07% |
| 2017 Q3 | 2.43 Billion USD | 0.78% |
| 2017 Q1 | 2.31 Billion USD | -3.69% |
| 2017 Q2 | 2.41 Billion USD | 4.05% |
| 2017 Q4 | 2.79 Billion USD | 15.08% |
| 2017 FY | 9.95 Billion USD | 12.96% |
| 2016 FY | 8.81 Billion USD | 7.73% |
| 2016 Q1 | 2.05 Billion USD | -6.95% |
| 2016 Q3 | 2.16 Billion USD | -1.01% |
| 2016 Q4 | 2.4 Billion USD | 11.23% |
| 2016 Q2 | 2.18 Billion USD | 6.16% |
| 2015 FY | 8.18 Billion USD | 3.33% |
| 2015 Q1 | 1.93 Billion USD | -7.73% |
| 2015 Q2 | 2.04 Billion USD | 6.15% |
| 2015 Q3 | 1.99 Billion USD | -2.83% |
| 2015 Q4 | 2.21 Billion USD | 11.13% |
| 2014 Q4 | 2.09 Billion USD | 2.32% |
| 2014 Q1 | 1.71 Billion USD | 11.45% |
| 2014 Q2 | 1.96 Billion USD | 14.56% |
| 2014 Q3 | 2.04 Billion USD | 4.26% |
| 2014 FY | 7.91 Billion USD | 37.7% |
| 2013 Q2 | 1.41 Billion USD | 1.92% |
| 2013 Q1 | 1.39 Billion USD | 0.45% |
| 2013 FY | 5.75 Billion USD | 4.25% |
| 2013 Q4 | 1.53 Billion USD | 9.43% |
| 2013 Q3 | 1.4 Billion USD | -1.1% |
| 2012 Q3 | 1.35 Billion USD | -1.56% |
| 2012 Q2 | 1.37 Billion USD | 2.07% |
| 2012 Q1 | 1.34 Billion USD | -0.8% |
| 2012 FY | 5.51 Billion USD | 10.59% |
| 2012 Q4 | 1.38 Billion USD | 2.42% |
| 2011 Q4 | 1.35 Billion USD | 6.8% |
| 2011 Q1 | 1.15 Billion USD | -0.71% |
| 2011 Q2 | 1.2 Billion USD | 4.52% |
| 2011 Q3 | 1.27 Billion USD | 5.43% |
| 2011 FY | 4.98 Billion USD | 9.07% |
| 2010 FY | 4.57 Billion USD | 10.22% |
| 2010 Q4 | 1.16 Billion USD | 2.71% |
| 2010 Q3 | 1.13 Billion USD | 1.38% |
| 2010 Q2 | 1.11 Billion USD | -1.27% |
| 2010 Q1 | 1.13 Billion USD | -0.71% |
| 2009 Q4 | 1.13 Billion USD | 9.26% |
| 2009 FY | 4.14 Billion USD | -1.35% |
| 2009 Q2 | 1.01 Billion USD | 14.84% |
| 2009 Q3 | 1.04 Billion USD | 2.29% |
| 2009 Q1 | 886.9 Million USD | -16.88% |
| 2008 Q4 | 1.06 Billion USD | 3.31% |
| 2008 FY | 4.2 Billion USD | 10.56% |
| 2008 Q1 | 1.01 Billion USD | -2.07% |
| 2008 Q2 | 1.08 Billion USD | 6.84% |
| 2008 Q3 | 1.03 Billion USD | -5.08% |
| 2007 Q1 | 879.9 Million USD | 48.12% |
| 2007 Q4 | 1.03 Billion USD | 9.68% |
| 2007 FY | 3.8 Billion USD | 142.62% |
| 2007 Q2 | 936.6 Million USD | 6.44% |
| 2007 Q3 | 948.1 Million USD | 1.23% |
| 2006 FY | 1.56 Billion USD | 31.22% |
| 2006 Q1 | 312.62 Million USD | -8.74% |
| 2006 Q3 | 336.88 Million USD | 3.82% |
| 2006 Q4 | 594.05 Million USD | 76.34% |
| 2006 Q2 | 324.49 Million USD | 3.8% |
| 2005 Q4 | 342.56 Million USD | 12.06% |
| 2005 FY | 1.19 Billion USD | 17.79% |
| 2005 Q3 | 305.69 Million USD | 6.35% |
| 2005 Q2 | 287.45 Million USD | 10.89% |
| 2005 Q1 | 259.23 Million USD | -8.65% |
| 2004 Q3 | 250.95 Million USD | 5.05% |
| 2004 Q1 | 264.58 Million USD | -0.21% |
| 2004 FY | 1.01 Billion USD | 7.01% |
| 2004 Q4 | 283.77 Million USD | 13.08% |
| 2004 Q2 | 238.88 Million USD | -9.71% |
| 2003 Q2 | 233.14 Million USD | 4.16% |
| 2003 Q3 | 225.9 Million USD | -3.11% |
| 2003 Q4 | 265.12 Million USD | 17.36% |
| 2003 Q1 | 223.83 Million USD | -8.74% |
| 2003 FY | 948.01 Million USD | 2.23% |
| 2002 FY | 927.37 Million USD | -3.26% |
| 2002 Q3 | 228.65 Million USD | -0.49% |
| 2002 Q2 | 229.78 Million USD | 2.74% |
| 2002 Q1 | 223.65 Million USD | -5.56% |
| 2002 Q4 | 245.27 Million USD | 7.27% |
| 2001 Q4 | 236.82 Million USD | 3.65% |
| 2001 FY | 958.62 Million USD | -6.19% |
| 2001 Q3 | 228.48 Million USD | -4.02% |
| 2001 Q2 | 238.06 Million USD | -6.74% |
| 2001 Q1 | 255.25 Million USD | 66.9% |
| 2000 Q4 | 152.94 Million USD | -43.25% |
| 2000 FY | 1.02 Billion USD | -15.29% |
| 2000 Q3 | 269.5 Million USD | -10.6% |
| 2000 Q1 | 297.93 Million USD | 2.37% |
| 2000 Q2 | 301.44 Million USD | 1.18% |
| 1999 Q2 | 281.18 Million USD | 15.41% |
| 1999 FY | 1.2 Billion USD | -34.55% |
| 1999 Q1 | 243.63 Million USD | -47.33% |
| 1999 Q4 | 291.04 Million USD | 5.13% |
| 1999 Q3 | 276.83 Million USD | -1.55% |
| 1998 FY | 1.84 Billion USD | 7.11% |
| 1998 Q1 | 448.7 Million USD | -7.77% |
| 1998 Q2 | 463.8 Million USD | 3.37% |
| 1998 Q3 | 463.9 Million USD | 0.02% |
| 1998 Q4 | 462.6 Million USD | -0.28% |
| 1997 FY | 1.72 Billion USD | 23.78% |
| 1997 Q4 | 486.5 Million USD | 9.99% |
| 1997 Q3 | 442.3 Million USD | 12.52% |
| 1997 Q2 | 393.1 Million USD | 18.15% |
| 1997 Q1 | 332.7 Million USD | -27.88% |
| 1996 FY | 1.39 Billion USD | 28.39% |
| 1996 Q1 | 270.4 Million USD | -25.82% |
| 1996 Q4 | 461.3 Million USD | 39.45% |
| 1996 Q2 | 317.8 Million USD | 17.53% |
| 1996 Q3 | 330.8 Million USD | 4.09% |
| 1995 Q2 | 242.3 Million USD | 10.09% |
| 1995 Q4 | 364.5 Million USD | 42.44% |
| 1995 Q3 | 255.9 Million USD | 5.61% |
| 1995 Q1 | 220.1 Million USD | -9.61% |
| 1995 FY | 1.08 Billion USD | 50.58% |
| 1994 Q2 | 162.1 Million USD | 13.83% |
| 1994 Q3 | 171.2 Million USD | 5.61% |
| 1994 Q4 | 243.5 Million USD | 42.23% |
| 1994 FY | 719 Million USD | 33.99% |
| 1994 Q1 | 142.4 Million USD | -21.54% |
| 1993 Q2 | 115.1 Million USD | -6.73% |
| 1993 Q4 | 181.5 Million USD | 39.72% |
| 1993 Q1 | 123.4 Million USD | -8.32% |
| 1993 Q3 | 129.9 Million USD | 12.86% |
| 1993 FY | 536.6 Million USD | 45.34% |
| 1992 Q3 | 92.6 Million USD | 22.65% |
| 1992 Q4 | 134.6 Million USD | 45.36% |
| 1992 Q1 | 66.5 Million USD | -26.6% |
| 1992 Q2 | 75.5 Million USD | 13.53% |
| 1992 FY | 369.2 Million USD | 25.03% |
| 1991 Q3 | 66.6 Million USD | -0.75% |
| 1991 Q4 | 90.6 Million USD | 36.04% |
| 1991 Q1 | 65.8 Million USD | -27.61% |
| 1991 FY | 295.3 Million USD | 11.43% |
| 1991 Q2 | 67.1 Million USD | 1.98% |
| 1990 Q3 | 69.5 Million USD | 15.45% |
| 1990 Q4 | 90.9 Million USD | 30.79% |
| 1990 Q1 | 49.1 Million USD | -9.41% |
| 1990 Q2 | 60.2 Million USD | 22.61% |
| 1990 FY | 265 Million USD | 35.97% |
| 1989 Q1 | 137.2 Million USD | -8.72% |
| 1989 FY | 194.9 Million USD | 11.44% |
| 1989 Q4 | 54.2 Million USD | 17.06% |
| 1989 Q2 | 150.8 Million USD | 9.91% |
| 1989 Q3 | 46.3 Million USD | -69.3% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 15396.198% |
| Dynavax Technologies Corporation | 182.11 Million USD | -8259.461% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -2806.775% |
| Perrigo Company plc | 1.68 Billion USD | -805.975% |
| Illumina, Inc. | 2.74 Billion USD | -454.81% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 159246.979% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 42.603% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -190.59% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -151503.266% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | -34.709% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 77383.111% |
| Waters Corporation | 1.76 Billion USD | -764.414% |
| Biogen Inc. | 7.3 Billion USD | -108.485% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 33688.527% |
| Evolus, Inc. | 140.52 Million USD | -10733.582% |
| Adicet Bio, Inc. | -6.09 Million USD | 249755.625% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -102806.584% |
| bluebird bio, Inc. | -4.03 Million USD | 377866.749% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -20735.671% |
| FibroGen, Inc. | 128.9 Million USD | -11710.339% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -339.365% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 48945.502% |
| Homology Medicines, Inc. | -7.22 Million USD | 210696.21% |
| Geron Corporation | -123.5 Million USD | 12426.826% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -902.974% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -4105.176% |
| Myriad Genetics, Inc. | 476.4 Million USD | -3095.634% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 5213798.63% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 3917.51% |
| Zoetis Inc. | 5.83 Billion USD | -160.953% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -5040959.603% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -601.867% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -699.424% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | -76.879% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 5024522.442% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -1855.52% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 4863997.764% |
| Verastem, Inc. | -62 Thousand USD | 24554938.71% |
| Nektar Therapeutics | 53.47 Million USD | -28367.781% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -6125.694% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 17965.19% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -1292.873% |
| OPKO Health, Inc. | 318.12 Million USD | -4685.51% |
| Exelixis, Inc. | 1.75 Billion USD | -766.151% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -724.077% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -3099.032% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -687213.77% |
| Imunon, Inc. | -720 Thousand USD | 2114529.761% |
| Blueprint Medicines Corporation | 236.58 Million USD | -6334.924% |
| Insmed Incorporated | 239.63 Million USD | -6252.995% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -2290.358% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -87803.459% |
| TG Therapeutics, Inc. | 219.1 Million USD | -6848.172% |
| Incyte Corporation | 3.44 Billion USD | -342.475% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -4326.868% |